Form 4: Pasithea CFO Receives Significant Stock Option Grant

Pasithea Therapeutics Corp.'s Chief Financial Officer, Daniel H. Schneiderman, was granted 317,266 stock options with an exercise price of $0.715.

Summary

• Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA), was granted 317,266 stock options.
• The options have an exercise price of $0.715 per share.
• The grant date for these options was October 24, 2025.
• The options will expire on October 23, 2035.
• Vesting occurs at a rate of 33% upon the one-year anniversary of the grant date, with the remaining shares vesting in equal quarterly installments over the subsequent two years.
• Full vesting will occur immediately upon a Change in Control, as defined in the company's plan.
• The options were awarded under the Issuer's 2023 Stock Incentive Plan, as amended.
• Following the reported transaction, Daniel H. Schneiderman beneficially owns 317,266 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant) which is generally neutral but can be seen as slightly positive due to management alignment with shareholder interests. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• The options were granted under an existing, approved 2023 Stock Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule for the stock options incentivizes the Chief Financial Officer to remain in continuous service to the Issuer for at least three years from the grant date to achieve full vesting. The options' long expiration date provides a significant window for potential value realization.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industry, including for companies like Pasithea Therapeutics, to attract, retain, and motivate key executives. This compensation structure is designed to align executive incentives with long-term shareholder value creation, particularly in sectors with long development cycles and significant R&D investments.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns the Chief Financial Officer's financial interests with long-term shareholder value creation, potentially leading to more focused management decisions aimed at increasing stock price.
• Employees: The grant is part of the company's executive compensation strategy, which can influence overall employee morale and retention strategies, particularly for key personnel.

Next Steps

• The stock options will begin to vest on the one-year anniversary of the grant date, October 24, 2025.
• Subsequent vesting will occur in equal quarterly installments over the following two years.

Key Dates

Keywords

Pasithea Therapeutics, KTTA, Stock Option, CFO, Executive Compensation, Insider Transaction, Form 4